With continued pricing pressure on its key molecules (gGlumetza, gFortamet and gMethergine) and lack of key launches, its US business is expected to report weak growthfrom Moneycontrol Market Outlook http://bit.ly/2TA5faf
Tuesday, February 5, 2019
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment